Myeloma Paper of the Day, July 25th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Retrospective study finds that, among BCMA-directed therapies, CAR T-cells & T-cell engagers yield better outcomes vs. ADCs, but their efficacy is most impacted by prior BCMA-targeted therapy among the three classes of agents.”
Source: Robert Orlowski/X
Authors: Matthew J Rees, Aytaj Mammadzadeh, Abiola Bolarinwa, Mohammed E Elhaj, Arwa Bohra, Radhika Bansal, Sikander Ailawadhi, Ricardo Parrondo, Saurabh Chhabra, Amit Khot, Suzanne Hayman, Angela Dispenzieri, Francis Buadi, David Dingli, Rahma Warsame, Prashant Kapoor, Morie A Gertz, Eli Muchtar, Taxiarchis Kourelis, Wilson Gonsalves, S Vincent Rajkumar, Yi Lin, and Shaji Kumar.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
